1. Wearing stars and hats may be delisted
Previously, due to the statement "uncertainty in the ability to continue operations" in the 2022 audit report, and the operating income in 2022 was less than 100 million yuan, the company was implemented "delisting risk warning" and continued to be implemented "other risk warnings" since the market opened on April 27, 2023, and the company's abbreviation was changed from "ST Tianshan" to "*ST Tianshan", and the company had continuous performance losses and negative news, and was repeatedly questioned by regulators and hovered on the verge of delisting. As of the end of the third quarter of 2023, the company's revenue was 11.3 billion yuan, net profit attributable to shareholders of listed companies was -1303750,000 yuan. Whether the company can be revoked in 2023 depends on whether the company's relevant financial indicators in 2023 meet the conditions for applying for withdrawal of delisting risk, but there is still uncertainty about this matter.
2. The shareholder lawsuit has been decided in the first instance
After Tianshan Biotech received a penalty from the China Securities Regulatory Commission in early April 2021, many injured investors signed up to defend their rights and filed a civil lawsuit against the company on the grounds of false statements, demanding compensation for investment losses. The Urumqi Intermediate People's Court has made a first-instance judgment in the case of Tianshan Biological's liability for false statements. The court held that Tianshan Biotech's material omission in information disclosure at the stage of asset restructuring also constituted a false statement and was material, and the investor should be compensated for the corresponding losses.
It is worth noting that on November 29, *ST Tianshan suddenly issued an announcement on major events, and the company was unable to get in touch with the company's chairman Ma through **, WeChat, etc., Ma was not only the chairman of Tianshan Biology but also the vice president of Zhongzhi Enterprise Group.
3. There is an urgent need to protect rights
According to the ** Law and several provisions on misrepresentation, if the information disclosure obligor causes damage to the investor due to the violation of the disclosure of the information, the investor may file a civil lawsuit to require the relevant responsible entity to compensate for the loss, including the loss of investment difference, commission and stamp duty. It is also necessary to remind investors that the statute of limitations for Tianshan Biopharma's claims will expire in April 2024, and if they participate in the protection of rights after the expiration, they will lose the right to win the lawsuit.
Investors who sold or still held after January 25, 2019 during the period from August 14, 2017 to January 24, 2019** can also participate in the rights protection registration on their own.